Literature DB >> 29414283

Beneficial effect of plasma exchange in acute attack of neuromyelitis optica spectrum disorders.

Tayanan Srisupa-Olan1, Sasitorn Siritho2, Kulvara Kittisares3, Jiraporn Jitprapaikulsan4, Chanjira Sathukitchai5, Naraporn Prayoonwiwat6.   

Abstract

BACKGROUND: Plasma exchange (PLEX) is routinely performed in neuromyelitis optica spectrum disorders (NMOSD) patients with an acute attack who do not respond to corticosteroids treatment.
OBJECTIVE: To compare treatment outcomes in NMOSD patients with an acute attack between the two groups.
METHODS: We retrospectively studied 67 attacks from 52 NMOSD patients. Outcome measurements using Expanded Disability Status Scale (EDSS), modified Rankin Scale (mRS) were compared.
RESULTS: There were 23 IVMP responders, 16 IVMP non-responders refusing PLEX, 12 IVMP non-responders/PLEX responders, and 16 IVMP/PLEX non-responders. The IVMP-responders showed faster improvement since the time of discharge but seemed to have less treatment benefit over time. However, IVMP non-responders/PLEX responders showed continuous and maximum improvement at 6 months (ΔEDSS from nadir: 1 for IVMP-responders vs 0.5 for IVMP non-responders without PLEX vs 2.75 IVMP non-responders/PLEX-responders vs 0.5 IVMP/PLEX non-responders; p = 0.49) and had comparable outcomes to the IVMP-responders (nadir EDSS 8.0 to 5.25 [ΔEDSS = 2.75] vs nadir EDSS 6.5 to 5.0; [ΔEDSS = 1.5], respectively).
CONCLUSION: Add - on PLEX treatment in NMOSD patients with an acute attack should be considered in those not responding to IVMP alone.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute attack; Add-on therapy; Methylprednisolone; Neuromyelitis optica; Plasma exchange; Treatment response

Mesh:

Year:  2018        PMID: 29414283     DOI: 10.1016/j.msard.2018.01.010

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  8 in total

1.  Differences in clinical features between optic neuritis in neuromyelitis optica spectrum disorders and in multiple sclerosis.

Authors:  Jindapa Srikajon; Sasitorn Siritho; Chanon Ngamsombat; Naraporn Prayoonwiwat; Niphon Chirapapaisan
Journal:  Mult Scler J Exp Transl Clin       Date:  2018-08-11

2.  CSF macrophage migration inhibitory factor levels did not predict steroid treatment response after optic neuritis in patients with multiple sclerosis.

Authors:  Marc Pawlitzki; Catherine M Sweeney-Reed; Sven G Meuth; Dirk Reinhold; Jens Neumann
Journal:  PLoS One       Date:  2018-11-26       Impact factor: 3.240

3.  Plasma Exchange as a First Line Therapy in Acute Attacks of Neuromyelitis Optica Spectrum Disorders.

Authors:  B L Kumawat; Reenu Choudhary; C M Sharma; Deepak Jain; Ashwini Hiremath
Journal:  Ann Indian Acad Neurol       Date:  2019-10-25       Impact factor: 1.383

4.  Predictive Factors of Resistance to High-Dose Steroids Therapy in Acute Attacks of Neuromyelitis Optica Spectrum Disorder.

Authors:  Chuan Qin; Ran Tao; Shuo-Qi Zhang; Bo Chen; Man Chen; Hai-Han Yu; Yun-Hui Chu; Ke Shang; Long-Jun Wu; Bi-Tao Bu; Dai-Shi Tian
Journal:  Front Neurol       Date:  2020-11-12       Impact factor: 4.003

5.  PLEX: the best first-line treatment in nmosd attacks experience at a single center in Colombia.

Authors:  C Restrepo-Aristizábal; L M Giraldo; Y M Giraldo; A M Pino-Pérez; F Álvarez-Gómez; C A Franco; J V Tobón; J L Ascencio; M I Zuluaga
Journal:  Heliyon       Date:  2021-04-17

Review 6.  Update on neuromyelitis optica spectrum disorder.

Authors:  Kathryn B Holroyd; Giovanna S Manzano; Michael Levy
Journal:  Curr Opin Ophthalmol       Date:  2020-11       Impact factor: 4.299

7.  Safety and efficacy of plasma exchange for the treatment of optic neuritis in neuromyelitis optica spectrum disorders: A protocol for systematic review and meta-analysis.

Authors:  Mengyu Han; You Chen; Luqi Nong; Ziqiang Liu; Lu Hao; Zhijun Wang
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

8.  Plasma Exchange or Immunoadsorption in Demyelinating Diseases: A Meta-Analysis.

Authors:  Mark Lipphardt; Manuel Wallbach; Michael J Koziolek
Journal:  J Clin Med       Date:  2020-05-25       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.